Drug Security as a Pillar of Health Protection

The transition to personalized medicine is one of the key frontiers in the evolution of modern healthcare. Drugs tailored to individual patient molecular and genetic profiles, including cellular technologies such as CAR-T and TCR-T therapies, are not only transforming clinical approaches to cancer treatment, but also the principles that govern financing, efficacy assessment, and access to medical care. For such technologies to be successfully introduced, it is crucial that their high clinical value offset manufacturing constraints and limited production volumes, and to also establish a fundamentally different economic model. Key drivers of progress include fundamental and applied scientific research in molecular and experimental medicine, the development of full-cycle technological platforms, the adoption of new approaches to the pharmacoeconomic assessment of advanced therapy medicinal products, as well as the use of artificial intelligence and digital solutions to inform next-generation clinical decision-making. What mechanisms could be used to synchronize scientific, manufacturing, and regulatory decisions regarding the introduction of personalized oncology technologies? What new approaches to pharmacoeconomic assessments need to be adapted for CAR-T and TCR-T therapies? How can we strike a balance between accelerating the market launch of innovative oncology drugs and maintaining high standards of safety and efficacy in the context of small-batch and piecework production? How are artificial intelligence and real-world clinical data being integrated into such processes as molecular diagnostics, patient selection, and the assessment of the long-term efficacy of personalized therapies?